“Ovarian aging is associated with a progressive physiological decline in the quantity and quality of the oocytes.”
BUFFALO, NY- September 24, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 17 on September 13, 2024, entitled, “Intraovarian PRP injection improves oocyte quality and early embryo development in mouse models of chemotherapy-induced diminished ovarian reserve.”
Ovarian aging leads to a gradual decline in both the quantity and quality of oocytes, impacting fertility. Over the past two decades, more individuals have sought fertility treatments due to delayed childbearing, contributing to diminished ovarian reserves. Recently, intraovarian injection of platelet-rich plasma (PRP) has emerged as a promising treatment for patients diagnosed with poor ovarian reserve (POR) or premature ovarian insufficiency (POI), showing positive and encouraging outcomes.
In this paper, researchers Mauro Cozzolino, Yagmur Ergun, Denis A. Seli, and Sonia Herraiz from IVIRMA Global Research Alliance, IVI Foundation -IIS la Fe, Department of Obstetrics, Gynecology and Reproductive Sciences and IVIRMA Roma first induced POR and POI ovarian phenotypes in CD1 mice, followed by PRP or sham intraovarian injection.
The authors demonstrated that PRP intraovarian injection can improve the number and quality of blastocysts in POI mouse ovaries damaged by high doses of chemotherapy. They also aimed to characterize the protein content of PRP and investigated whether PRP improves reproductive function in different mouse strains with chemotherapy-induced POR and POI.
“Altogether, our findings suggest a possible effect of the local injection of PRP on blastocyst formation and quality.”
Continue reading: DOI: https://doi.org/10.18632/aging.206099
Correspondence Author: Sonia Herraiz – sonia.herraiz@ivirma.com
Video short: https://www.youtube.com/watch?v=8C-AssalQsU
Keywords: platelet-rich plasma ovarian injection, poor ovarian reserve, premature ovarian insufficiency
Click here to sign up for free Altmetric alerts about this article.
About Aging:
The journal Aging aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
- X
- YouTube
- Spotify, and available wherever you listen to podcasts
Click here to subscribe to Aging publication updates.
For media inquiries, please contact media@impactjournals.com.
Aging (Aging-US) Journal Office
6666 E. Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1
Journal
Aging-US
Method of Research
News article
Subject of Research
Animals
Article Title
Intraovarian PRP injection improves oocyte quality and early embryo development in mouse models of chemotherapy-induced diminished ovarian reserve
Article Publication Date
13-Sep-2024
COI Statement
The authors declare no conflicts of interest related to this study.